AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
Completed
- Conditions
- Treatment of Acute Coronary Syndrome (ACS).
- Interventions
- Drug: ACS patients treated with OAP
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT02190123
- Locations
- 🇧🇪
Research Site, Ukkel, Belgium
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02189252
- Locations
- 🇨🇦
Research Site, Chocoutimi, Quebec, Canada
Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2577
- Registration Number
- NCT02187926
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Phase 3
Completed
- Conditions
- Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT02184195
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
Clopidogrel Bioequivalence Study in Healthy Subjects
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT02185534
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Phase 2
Completed
- Conditions
- Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02179671
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT02178059
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2133
- Registration Number
- NCT02174731
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2781
- Registration Number
- NCT02174627
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1323
- Registration Number
- NCT02165826